Related Experiment Videos
Early vasodilator treatment in myocardial infarction: appropriate for the majority or minority?
A D Hargreaves1, T Kolettis, A J Jacob
1Department of Medicine, Royal Infirmary, Edinburgh.
Insights
Early vasodilator treatment after myocardial infarction showed no significant impact on left ventricular function. Captopril may offer benefits for high-risk patients, but overall, vasodilator therapy has limited value, especially with thrombolysis.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Early intervention post-myocardial infarction (MI) is crucial for improving patient outcomes.
- The role of vasodilators in modulating left ventricular remodeling after acute MI requires further investigation.
Purpose of the Study:
- To evaluate the effect of early vasodilator treatment on left ventricular size and function following acute myocardial infarction.
Main Methods:
- A double-blind, randomized, placebo-controlled trial involving 105 acute myocardial infarction patients.
- Patients received either captopril or isosorbide mononitrate for 28 days, with 88% also receiving thrombolysis.
- Left ventricular size and function were assessed using echocardiography, radionuclide ventriculography, and MRI.
Main Results:
- No significant differences in left ventricular size or function were observed between vasodilator and placebo groups one week post-treatment.
- A slight, non-significant decrease in left ventricular diameter was noted in the placebo group over the study period.
- Fewer adverse clinical outcomes occurred in the captopril group compared to the placebo group.
Conclusions:
- Vasodilator therapy offers limited or no benefit for most myocardial infarction patients, particularly those receiving thrombolytic agents.
- Captopril may provide a clinical advantage for high-risk individuals post-myocardial infarction.
Objective:
To assess the influence of vasodilator treatment started early after myocardial infarction on left ventricular size and function.
Setting:
Coronary care unit, Royal Infirmary, Edinburgh.
Patients:
105 patients with acute myocardial infarction (systolic blood pressure > 90 mm Hg) were randomised within 24 hours of the start of pain. Unlike previous studies 88% of the patients received thrombolysis.
Methods:
Double blind randomised placebo controlled study with either 12.5 mg of captopril three times daily or 20 mg of isosorbide mononitrate three times daily for 28 days.
Main Outcome Measures:
Clinical outcome and left ventricular size and function assessed by echocardiography, radionuclide ventriculography, and magnetic resonance imaging.
Results:
There was no difference in left ventricular size or function in either treatment group as measured one week after the end of the trial. Even the placebo group tended to decrease left ventricular diameter over the four week study period (one week: 5.0 (0.1) v, five weeks: 4.8 (0.1) cm, NS). Four patients had an adverse clinical outcome in the placebo group whereas no adverse outcome was seen in the captopril group.
Conclusions:
Vasodilator treatment may be of limited value or of no benefit for most infarct patients, particularly those treated with thrombolytic agents. Captopril, however, may benefit patients at high risk.